LONDON - Amgen Inc. received a double blow against the patent covering its blockbuster drug erythropoietin (EPO) when the UK House of Lords reversed an earlier legal decision and ruled the claims of the patent are too broad, while at the same time upholding an earlier judgment that Transkaryotic Therapies Inc.'s method of producing EPO does not infringe Amgen's EPO patent. (BioWorld International)

LONDON - Allergy Therapeutics Ltd. met the target of £15 million (US$26.7 million) in its listing on the Alternative Investment Market in London, but fell short of the hoped-for valuation of £55 million, placing 23 million shares at 73 pence each for a market capitalization of £46 million. (BioWorld International)

LONDON - Allergy Therapeutics Ltd. met the target of £15 million (US$26.7 million) in its listing on the Alternative Investment Market in London, but fell short of the hoped-for valuation of £55 million, placing 23 million shares at 73 pence each for a market capitalization of £46 million. (BioWorld International)